Journal: Frontiers in Endocrinology
Article Title: Clozapine Induced Disturbances in Hepatic Glucose Metabolism: The Potential Role of PGRMC1 Signaling
doi: 10.3389/fendo.2021.727371
Figure Lengend Snippet: Illustrative model of the mechanism focusing on hepatic PGRMC1 signaling underlying chronic CLZ-induced hepatic glucose disturbances. The add-on PGRMC1-OE can reverse CLZ-induced hepatic glucose disturbances by upregulating the expression of PGRMC1-EGFR/GLP1R-PI3K-Akt-GSK3β accompanied with the downregulation of nuclear FOXO1. CLZ, CLZ; AG205, the specific inhibitor of PGRMC1; PGRMC1-KD, the knockdown of PGRMC1; PGRMC1-OE, the overexpression of PGRMC1; H&E, hematoxylin and eosin staining; PAS, Periodic acid–Schiff staining; PGRMC1, PROG receptor membrane component 1; EGFR, epidermal growth factor receptor; GLP1R, glucagon-like peptide-1 receptor; PI3K, 3-phosphoinositide-dependent kinase-1; Akt, protein kinase B; GSK3β, glycogen synthase kinase-3β; FOXO1, the fork head box protein 1.
Article Snippet: Approximately 20 μg of protein was loaded, electrophoresed, blotted and then incubated with primary antibodies against PGRMC1, EGFR, GLP1R, PI3K p85, Akt, phospho-Akt (Ser 473 ), GSK-3β, FOXO1, β-actin, PCNA (Proteintech Group, Wuhan, China), phospho-EGFR, phospho-GSK-3β (Affinity) overnight at 4°C.
Techniques: Expressing, Knockdown, Over Expression, Staining, Membrane